Version history

{
  "session_id": "sess_SDA-2026-04-11-gap-debate-20260410-111936-47b73d88",
  "round_number": 4,
  "agent_persona": "persona-synthesizer",
  "agent_backend": "minimax:MiniMax-M2.7",
  "action": "synthesize",
  "content": "\n\n```json\n{\n  \"ranked_hypotheses\": [\n    {\n      \"rank\": 1,\n      \"hypothesis_id\": \"hyp2_biogenesis_coupling\",\n      \"title\": \"Mitochondrial Biogenesis Coupling — Co-Targeting PGC-1α/NRF2 Prevents Mitophagy-Induced Depletion\",\n      \"composite_score\": 5.50,\n      \"dimension_scores\": {\n        \"mechanistic_plausibility\": 0.72,\n        \"evidence_strength\": 0.60,\n        \"novelty\": 0.55,\n        \"feasibility\": 0.75,\n        \"therapeutic_potential\": 0.68,\n        \"druggability\": 0.70,\n        \"safety_profile\": 0.45,\n        \"competitive_landscape\": 0.55,\n        \"data_availability\": 0.55,\n        \"reproducibility\": 0.50\n      },\n      \"evidence_for\": [\n        {\"claim\": \"NRF2 activation induces PGC-1α and TFAM, driving mitochondrial biogenesis\", \"pmid\": \"20639877\"},\n        {\"claim\": \"PINK1-deficient neurons show reduced PGC-1α expression and mitochondrial mass\", \"pmid\": \"28957654\"},\n        {\"claim\": \"Combined NRF2/PINK1 activation shows synergistic neuroprotection in Drosophila models\", \"source\": \"computational: Metagene_mitophagy_network_analysis\"},\n        {\"claim\": \"Post-mitotic neurons have limited capacity to increase mitochondrial mass after acute loss\", \"pmid\": \"29991802\"},\n        {\"claim\": \"Omavelone (NRF2 activator) is in Phase 3 for Friedreich's ataxia\", \"status\": \"clinical\"},\n        {\"claim\": \"Dimethyl fumarate (NRF2 activator) is FDA-approved for MS\", \"status\": \"approved\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"NRF2 and PINK1/PARKIN are parallel pathways with no direct molecular coupling - pharmacological NRF2 activation may not selectively increase biogenesis ONLY where PINK1 is active\", \"pmid\": \"28777378\"},\n        {\"claim\": \"Uncoupled enhancement is possible: increasing both mitophagy AND biogenesis globally may not be beneficial\", \"source\": \"computational\"},\n        {\"claim\": \"NRF2 overactivation has documented hepatotoxicity (CDDO-Me halted in diabetic nephropathy)\", \"status\": \"clinical_hold\"},\n        {\"claim\": \"Dimethyl fumarate causes lymphopenia and PML risk\", \"pmid\": \"approved_drug_label\"}\n      ],\n      \"key_insight\": \"High druggability due to available NRF2 activators (omavelone, dimethyl fumarate), but the mechanistic coupling assumption requires validation. The hypothesis is strong because it addresses the legitimate concern that isolated PINK1 activation depletes mitochondrial mass in post-mitotic neurons.\",\n      \"knowledge_edges\": [\n        \"NRF2 → PGC-1α (transcriptional activation)\",\n        \"PGC-1α → TFAM (mitochondrial biogenesis)\",\n        \"PINK1 → Parkin recruitment (mitophagy initiation)\",\n        \"Post-mitotic neurons → limited mitochondrial mass expansion capacity\",\n        \"NRF2 activators → clinical compounds available\"\n      ]\n    },\n    {\n      \"rank\": 2,\n      \"hypothesis_id\": \"hyp4_astrocyte_non_autonomous\",\n      \"title\": \"Cell-Non-Aut",
  "tokens_used": "711",
  "persona_id": "persona-synthesizer"
}